Prolactin secretion in polycystic ovary syndrome: circadian rhythmicity and dynamic aspects

References

• Judd S. J., Rigg L. A., Yen S. S. C. The effects of ovariectomy and estrogen treatment on the dopamine inhibition of gonadotropin and prolactin release. J. Clin. Endocrinol. Metab. 1976; 49: 182
   Google Scholar
• Quigley M. E., Rakoff J. S., Yen S. S. C. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 1981; 52: 231
   PubMed Web of Science ®Google Scholar
• Luciano A. A., Chapler F. K., Sherman B. M. Hyperprolactinemia in polycystic ovary syndrome. Fertil. Steril. 1984; 41: 719
   PubMed Web of Science ®Google Scholar
• Cumming D. C., Reid R. L., Quigley M. E., Rebar R. W., Yen S. S. C. Evidence for decreased endogenous dopamine and opiod inhibitory influences on LH-secretion in polycystic ovary syndrome. Clin. Endocrinol. 1984; 20: 643
   PubMed Web of Science ®Google Scholar
• Futterweit W., Krieger D. T. Pituitary tumors associated with hyperprolactinemia and polycystic ovarian disease. Fertil. Steril. 1979; 31: 608
   PubMed Web of Science ®Google Scholar
• Yen S. S. C. The polycystic ovary syndrome. Clin. Endocrinol. 1980; 12: 177
   PubMed Web of Science ®Google Scholar
• Wortsman J., Hirschowitz J. S. Galactorrhea and hyperprolactinemia during treatment of polycystic ovary syndrome. Obstet. Gynecol. 1980; 55: 460
   PubMedGoogle Scholar
• Falaschi P., DelPozo E., Rocco A., Toscano V., Petrangeli E., Pompei P., Frajese G. Prolactin release in polycystic ovary. Obstet. Gynecol. 1980; 55: 579
   PubMed Web of Science ®Google Scholar
• Valkov I., Dokunov S. The pituitary FSH, LH, TSH and prolactin reserves in patients with polycystic ovary syndrome. Endokrynologia Polska 1977; 28: 429
   PubMedGoogle Scholar
• Messina M., Novi R. F., Ghigo E., Milani P., Camerano A., Molinatti G. M. Prolactin secretion in patients with polycystic ovary syndrome. Panminerva Medica 1985; 27: 79
   PubMedGoogle Scholar
• Murdoch A. P., Dunlop W., Kendall-Taylor P. Studies of prolactin secretion in polycystic ovary syndrome. Clin. Endocrinol. 1986; 24: 165
   PubMedGoogle Scholar
• Corenblum B., Taylor P. J. The hyperprolactinemic polycystic ovary syndrome may not be a distinct entity. Fertil. Steril. 1982; 38: 549
   PubMed Web of Science ®Google Scholar
• Falaschi P., DelPozo E., Rosa M., Rocco A. Prolactin and LH-secretion in polycystic ovary syndrome. Dopamine and Neuroendocrine Active Substances, p. 135, E. Del Pozo, E. Flückier. Academic Press Inc., London 1985
   Google Scholar
• Algez M., Vasquez-Matute L., Mason M., Canales E. S., Zarate A. Polycystic ovarian disease associated with hyperprolactinemia and defective metoclopramide response. Fertil. Steril. 1980; 34: 70
   PubMedGoogle Scholar
• Buvat J., Buvat-Herbaut M., Marcolin G., Racadot A., Couplet G., Fossati P. Hyperprolactinemia of polycystic ovary syndrome seems to result from a dopaminergic defect also acting in elevated serum LH levels. Horm. Res. 1985; 22: 247
   Google Scholar
• Thorner M. O., McNeilly A. S., Hagan C., Besser G. M. Long-term treatment of galactorrhea and hypogonadism with bromocriptine. Br. Med. J. 1974; 2: 419
   PubMed Web of Science ®Google Scholar
• Rocco A., Falaschi P., Pompei P., DelPozo E., Frajese G. Chronic anovulation in polycystic ovary syndrome: role of hyperprolactinemia and its suppression with bromocriptine. Psychoneuroendocrinology in Reproduction, p. 387, L. Zichella, P. Pancheri. Elsevier/North Holland Biomedical Press, Amsterdam 1979
   Google Scholar
• Hyyppa M. T., Liira J., Langvik V. A. Neuroendocrine aspects of neurology. Ann. Clin. Res. 1978; 10: 133
   PubMedGoogle Scholar
• Berger M. J., Taymor M. L., Patton W. C. Gonadotropin levels and secretory patterns in patients with typical and atypical polycystic ovarian disease. Fertil. Steril. 1975; 26: 619
   PubMedGoogle Scholar
• Halberg F. Chronobiology. Ann. Rev. Physiol. 1969; 31: 675
   PubMed Web of Science ®Google Scholar
• Bingham C., Arbogast B., Guillaume G. C., Lee J. K., Halberg F. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia 1982; IX: 397
   Google Scholar
• Buvat J., Siame-Mourot C., Fourlinnie J. C., Lemarie A., Buvat-Herbaut M., Hermhand E. Androgens and prolactin levels in hirsute women with either polycystic ovaries or ‘borderline ovaries’. Fertil. Stent. 1982; 38: 695
   PubMed Web of Science ®Google Scholar
• Carmina E., Rosato F., Maggiore M., Gagliano A. M., Indovina D., Janni A. Prolactin secretion in polycystic ovary syndrome: correlation with the steroid pattern. Acta Endocrinol. 1984; 105: 99
   PubMedGoogle Scholar
• Ehara Y., Slier T., Vanderberg G., Sinha Y. N., Yen S. S. C. Circulating prolactin levels during the menstrual cycle: episodic release and diurnal variation. Am. J. Obstet. Gynecol. 1973; 117: 962
   PubMedGoogle Scholar
• Marsden C. D. Basal ganglia disease. Lancet 1982; II: 1141
   Google Scholar
• Martignoni E., Murialdo G., Sances G., Giovale M., Nappi G., Savoldi F. Deteriorated regulation of prolactin periodicity in Parkinson's disease. Neuropeptides and Psychosomatic Processes, p. 661, E. Endroczy, D. De Wied, L. Angelucci, V. Scapagnini. Elsevier, Amsterdam 1983
   Google Scholar
• Ferrari E., Nappi G., Martignoni E., Micieli G., Pulvirenti L., Bossolo P. A., Magnani L. The circadian rhythm of plasma prolactin and temperature in Parkinson's disease. 1st Symposium of the European Neuroendocrinological Association. (E.N.E.A.), Basle March 4–7, 1984
   Google Scholar
• Yen S. S. C. Studies of the role of dopamine in the control of prolactin and gonadotropin secretion in humans. Central Regulation of the Endocrine System, p. 387, K. Fuxe, T. Höckfelt, R. Luft. Plenum Press, New York 1979
   Google Scholar